Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

1. XPO1: From basic research to clinical treatment (Review).Oncology reports · 2026
   Review
2. Effect of Polyphenols Derived from Medicinal Plants on Multiple Myeloma via Modulating Bone Marrow Microenvironment.Chinese journal of integrative medicine · 2026
   Review
3. Targeting the Ubiquitin-Proteasome System for Cancer.MedComm · 2025
   Review
4. Global trends and collaborations in bortezomib-induced neurotoxicity research: a bibliometric analysis (2002-2024).Frontiers in pharmacology · 2025
   Article
5. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.Frontiers in oncology · 2024
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as